AstraZeneca plc

09/18/2021 | Press release | Distributed by Public on 09/18/2021 05:34

Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

First HER2-directed therapy to show a strong tumour response in this population

Data from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial presented at ESMO and published in The New England Journal of Medicine